|
 The trial for the recombinant protein-based vaccine will take place
in Japan and follows a Phase I trial in the country, Shionogi said
in a statement. The company will also prepare to conduct multiple
trials globally, it said.
Medicines usually have to pass three phases of clinical trials
before they can be assessed for approval by regulators.
Separately, Daiichi Sankyo Co said it planned to start a Phase II
trial for its COVID-19 vaccine candidate next month.
[to top of second column] |
 The Japanese drugmaker is aiming for commercialization of the
mRNA-type vaccine, known as DS-5670, in 2022, it said in a
statement.
(Reporting by Rocky Swift Editing by Jacqueline Wong and Mark
Potter)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
